Related Experiment Video

Updated: Jun 16, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.0K

Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RASmut

Jin Wu1, Jianxin Wang1, Thomas N O'Connor1

  • 1Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Molecular Cancer Therapeutics
|August 16, 2024
PubMed

Insights

Combining CDK4/6 and MEK inhibitors, like palbociclib and trametinib, shows promise for soft tissue sarcomas by halting cell growth and activating immune pathways. This strategy offers new therapeutic avenues for RAS-mutant cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • CDK4/6 and MEK inhibitors are emerging cancer therapies, particularly effective in RAS-mutant cancers.
  • A high-throughput screen revealed synergistic effects between palbociclib (CDK4/6 inhibitor) and trametinib (MEK inhibitor) in soft tissue sarcomas.

Purpose of the Study:

  • To investigate the mechanistic basis for the synergistic efficacy of combined CDK4/6 and MEK inhibition in soft tissue sarcomas.
  • To explore the impact of RB1 status on treatment response and identify associated molecular pathways.

Main Methods:

  • Utilized drug screening, cell culture, CRISPR-mediated gene depletion (RB1), and xenograft models.
  • Performed cell cycle analysis, proliferation assays, and pathway enrichment analysis.
  • Investigated the role of TANK-binding kinase 1 (TBK1) using the inhibitor GSK8612.

Main Results:

  • Combination therapy induced significant G1 cell cycle arrest and reduced proliferation in RAS-mutant soft tissue sarcoma models.
  • RB1 depletion diminished the response to combined CDK4/6 and MEK inhibition, confirmed in vitro and in vivo.
  • Treatment activated interferon pathways and upregulated retroviral elements, with TBK1 inhibition selectively blocking these interferon-related gene expressions.

Conclusions:

  • Combined CDK4/6 and MEK inhibition is a promising therapeutic strategy for soft tissue sarcomas, particularly those with RAS mutations.
  • RB1 status is a critical determinant of response to this combination therapy.
  • The combination elicits separable cell cycle and epigenetic responses, including interferon pathway activation, offering insights into novel therapeutic combinations.

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.0K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.1K
Separation of Sister Chromatids02:17

Separation of Sister Chromatids

At the transition from prophase to metaphase, there is a reduction in cohesion along the chromosomal arms, resulting in the resolution of sister chromatids. However, residual cohesin connections remain to hold the sister chromatids together until the transition from metaphase to anaphase. The residual connection prevents any premature separation of sister chromatids, blocking the risks of aneuploidy within the daughter cells.
At the onset of anaphase, separase, a proteolytic enzyme, is...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.2K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.3K